South Korea is a key market for IQ-AI, with recent research estimating that there are about 300,000 new cases of kidney stone disease each year, despite having a relatively small population of 51mln
() has announced the first commercial sale of its StoneChecker kidney stone medical imaging software.
The company’s South Korean distributor received the order from a “prominent” hospital in the country.
“We are delighted to announce this significant commercial milestone for StoneChecker Software,” said IQ-AI chief operating officer David Smith.
“The enthusiasm and commercial interest with which the product has been greeted upon its introduction to South Korea bodes well for the global market. We look forward to making further announcements as we expand distribution.”
South Korea is a key market for IQ-AI, with recent research estimating that there are about 300,000 new cases of kidney stone disease each year, despite having a relatively small population of 51mln.
StoneChecker received European CE clearance last December, while approval from US regulators is expected soon.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE